Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06895746 · ClinicalTrials.gov registry record

Multi-omics Study in Citrin Deficiency

A clinical trial of Citrin Deficiency, sponsored by Johannes Haeberle.

Active
Registry status
100
Enrollment target
20
Study locations

NCT06895746: Active study of Citrin Deficiency, sponsored by Johannes Haeberle.

NCT06895746 is a study of Citrin Deficiency that is active but no longer recruiting, run by Johannes Haeberle. The registered enrollment target is 100 participants. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06895746, a study of Citrin Deficiency, is active but no longer recruiting, sponsored by Johannes Haeberle.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
20
Study locations

Study Summary

Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and dyslipidemia" form of CD (FTTDCD), and 4) citrullinemia type II (CTLN2), with the latter representing the final and most severe form of the condition. There is currently no cure for CD and patients manage their symptoms with lifelong dietary intervention and regular checkups with their physicians. A major hurdle in developing effective treatments for CD is the lack of effective biomarkers that track well with disease severity or measure the effectiveness of therapeutics. The present study aims to identify robust circulating biomarkers of CD through analysis of blood samples from CD patients.

Primary Outcome

The primary endpoint is the identification of biomarkers from CD patient-derived blood samples that are expressed at levels significantly different from matched controls.

Conditions Studied

Study Locations (20)

Other

  • Chiba Children's Hospital - Chiba
  • Kumamoto University Hospital - Kumamoto
  • Yamagata University School of Medicine - Yamagata
  • Taiwan University Hospital - Taipei
  • Taipei Veterans General Hospital - Taipei
  • University Hospitals Birmingham NHS Foundation Trust - Birmingham
  • Birmingham Women's and Children's Hospital NHF Foundation Trust - Birmingham
  • Bristol Royal Hospital for Children - Bristol
  • University College London Hospital - London

New York

  • Mount Sinai Hospital - New York

Fukuoka

  • Kurume University - Kurume-shi

Iruma

  • Saitama Medical University - Saitama

Kanagawa

  • Saiseikai Yokohama City Eastern Hospital - Yokohama

Minato City

  • Jikei University Hospital - Tokyo

Miyagi

  • Tohoku University - Sendai

Nagano

  • Shinshu University Hospital - Matsumoto

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-04-01
Est. Completion 2026-12
Johannes Haeberle

1 total trials

What the registry record for NCT06895746 still lists

NCT06895746 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Citrin Deficiency appearing as the primary indexed condition, and to 0 interventions.

NCT06895746 names 20 study sites across 12 states, led by Other, New York, Fukuoka.

Frequently Asked Questions

What is clinical trial NCT06895746 about?

NCT06895746 is a clinical study titled "Multi-omics Study in Citrin Deficiency". Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and dyslipidemia" form of CD (FTTDCD), and 4) citru...

What is the current status of trial NCT06895746?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-04-01. Estimated completion is 2026-12.

What conditions does trial NCT06895746 study?

This clinical trial studies the following conditions: Citrin Deficiency.

Who is sponsoring clinical trial NCT06895746?

This trial is sponsored by Johannes Haeberle, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06895746 being conducted?

This trial has 20 study locations across New York, Fukuoka, Iruma, Kanagawa, Minato City. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06895746, the US trial registry maintained by the National Library of Medicine. NCT06895746 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.